Vir Biotechnology's Triple Potential
This is a U.S. news story, published by Yahoo Finance, that relates primarily to Russell news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsRussell news
For more Russell news, you can click here:
more Russell newsstocks trading & speculation news
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
cap stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other stocks news, broader market challenges news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
global market dropsInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Business
Business & Economics
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple
84% Informative
U.S. small-cap stocks are struggling amid broader market challenges due to ongoing shifts in tariff policy.
The Russell index has fallen over 15% from its peak in November 2024 as of the time of writing this article.
However, the broader market has only dropped about 14% on a YTD basis.
Small-cap companies with international supply chains now face higher costs that could damage their profitability.
Vir Biotechnology, Inc. ( NASDAQ : VIR ) showed operational improvements for Q4 and FY24.
Q4 revenue was $12.4 million , down from $16.8 million a year earlier , whereas full-year revenue fell to $74.2 million from $ 86.2 .
The company ended 2024 with $1.10 billion in cash and cash equivalents and investments, down $532.3 million .
VR Score
88
Informative language
89
Neutral language
38
Article tone
semi-formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
1
Affiliate links
no affiliate links
Small business owner?